HA13831 Tranexamic Acid TXA Powder (CAS No.: 1197-18-8)

Tranexamic Acid TXA Powder (CAS No.: 1197-18-8) Description

Tranexamic Acid TXA Powder (CAS No.: 1197-18-8) is a chemically synthesised antifibrinolytic agent with the molecular structure C8H15NO2. It operates by inhibiting plasminogen activation, thereby reducing fibrinolysis. The powder's homogeneous particle size and crystalline consistency facilitate precise formulation in pharmaceutical manufacturing, ensuring accurate dosing and stability in clinical applications.

Tranexamic Acid TXA Powder (CAS No.: 1197-18-8) Characteristics

*The above product information is based on theoretical data and is for reference only. Actual specifications may vary.

Tranexamic Acid TXA Powder (CAS No.: 1197-18-8) Applications

Pharmaceutical Applications
- Used as an antifibrinolytic component in injectable formulations to reduce surgical blood loss by utilising its plasminogen inhibition properties.
- Applied in oral medications to control excessive menstrual bleeding by utilising its consistent purity and efficacy.

Research Applications
- Serves as a reagent in clinical studies to investigate antifibrinolytic mechanisms by offering reproducible chemical properties.
- Frequently used in bioassays to assess drug interactions due to its homogeneous crystalline structure.

Tranexamic Acid TXA Powder (CAS No.: 1197-18-8) Packing

Tranexamic Acid TXA Powder is packaged in moisture-proof, UV-resistant containers. The powder is sealed in high-density polyethylene pouches to prevent contamination and preserve its chemical integrity. Protective inner linings maintain ambient stability, and cushioned packaging reduces mechanical stress. Custom labelling and secondary carton options are available to meet specific shipping and storage requirements, ensuring optimal material presentation.

Additional Information

Tranexamic Acid, as a chemical reagent, plays a significant role in pharmaceutical sciences by modulating enzymatic processes involved in fibrinolysis. Its controlled synthesis and batch verification are crucial for achieving consistency in clinical applications. The material's crystalline structure ensures uniformity, aiding in reproducible dosing and predictable bioactivity.

Understanding the application of antifibrinolytic agents helps clarify their role in reducing excessive bleeding. Research in this domain has underscored the need for precise chemical formulations to support advanced therapeutic protocols, ensuring that each synthesised batch can reliably contribute to patient care and experimental outcomes.